Get the Daily Brief
Latest Biotech News
AI and physics model find Parkinson’s candidate — Gain Therapeutics announces mechanism‑based lead
Gain Therapeutics disclosed a drug discovered through an AI plus physics‑based modeling platform that allosterically binds a dysfunctional enzyme, restores its function, and reduces...
Human monoclonal antibodies neutralize clade 2.3.4.4b H5N1 — Nature Communications report
Researchers reported new human monoclonal antibodies that potently neutralize clade 2.3.4.4b H5N1 hemagglutinin, according to a Nature Communications paper. The antibodies show broad binding and...
Targeting ALKBH5 halts colorectal cancer stemness and resistance — Nature Communications discovery
A Nature Communications paper revealed that inhibiting the m6A RNA demethylase ALKBH5 suppresses colorectal cancer stemness and reverses chemoresistance in preclinical models. The study links...
LRBA inhibition degrades CTLA‑4 — new route to boost cancer immunity
A Nature Communications study found that targeting LRBA (lipopolysaccharide‑responsive and beige‑like anchor protein) promotes degradation of the immune checkpoint CTLA‑4 and enhances anti‑tumor...
China issues organoid guidelines — regulatory and ethical framework released
China published guidance on human organoid research, offering regulatory and bioethical direction for organoid generation, use, and oversight, the analysis reported. The guidelines address...
Sobi to buy Arthrosi: $950M upfront for Phase‑3 gout play
Sobi announced an acquisition agreement to buy Arthrosi Therapeutics, paying $950 million upfront with up to $550 million in contingent milestones. The deal brings a Phase 3 gout candidate into...
Structure’s oral GLP‑1 shocks investors – stock doubles after Phase II
Structure Therapeutics reported positive Phase II ACCESS results for aleniglipron, an oral GLP‑1 candidate, and shares surged more than 100% on the data. The mid‑stage readout showed clinically...
FDA clears Cardamyst: nasal arrhythmia spray approved after prior rejections
The FDA approved Milestone Pharmaceuticals’ nasally administered emergency treatment Cardamyst (etripamil) for a form of acute arrhythmia, after the drug was previously denied twice. The clearance...
Laguna Bio bets engineered Listeria on pediatric leukemia: living drug approach
Laguna Bio unveiled a microbial immunotherapy program that engineers an attenuated Listeria monocytogenes strain to stimulate multifactorial immune responses against cancer. Founders Jonathan...
New human antibodies neutralize clade 2.3.4.4b H5N1: potential pandemic countermeasure
Researchers led by Alzua and colleagues reported a panel of human monoclonal antibodies that potently neutralize clade 2.3.4.4b H5N1 hemagglutinin. Published in Nature Communications, the work...
SARS‑CoV‑2 nucleocapsid XEC mutation linked to more severe disease
A Nature Communications study by Tsujino, Tsuda, Deguchi and colleagues identified an XEC mutation in the SARS‑CoV‑2 nucleocapsid that increases viral pathogenicity independent of spike changes....
AI plus physics modeling surfaces a Parkinson’s drug candidate at Gain Therapeutics
Gain Therapeutics used an AI and physics‑based modeling platform to identify a novel small molecule that allosterically binds a dysfunctional enzyme, restores its activity, and reduces...
GLP‑1 agonist shows benefit in large‑vessel occlusion stroke trial
A phase 2 randomized trial published in Nature Communications led by Wang, Ko and Leung evaluated GLP‑1 receptor agonists in patients with large‑vessel occlusion (LVO) stroke undergoing...
Targeting ALKBH5 halts colorectal cancer stemness and chemoresistance
A Nature Communications study demonstrated that inhibiting the m6A RNA demethylase ALKBH5 suppresses colorectal cancer stemness and reverses chemoresistance. The authors linked ALKBH5 activity to...
Fucoidan enhances CAR‑T activity in lymphoma models: a natural adjuvant
Preclinical research reported that fucoidan, a seaweed‑derived sulfated polysaccharide, potentiates CAR‑T cell efficacy against non‑Hodgkin lymphoma by modulating the tumor microenvironment and...
Structure’s oral GLP-1 shocks investors: shares double after Phase II win
Structure Therapeutics reported positive mid-stage results from its Phase II ACCESS program for oral GLP-1 candidate aleniglipron, sending the company’s stock sharply higher. The company disclosed...
FDA clears nasal arrhythmia spray: Milestone’s Cardamyst approved
The FDA approved Milestone Pharmaceuticals’ nasally administered emergency treatment Cardamyst (etripamil) for acute supraventricular arrhythmias after two prior rejections. The approval provides...
Laguna Bio’s engineered Listeria... moves into leukemia testing
Laguna Bio unveiled a living‑drug platform built from a highly attenuated Listeria monocytogenes strain engineered to elicit multifactorial immune responses and activate rare gamma delta T cells....
Targeting ALKBH5 halts colorectal cancer stemness – study
Researchers published a Nature Communications study showing that the m6A RNA demethylase ALKBH5 sustains colorectal cancer stemness and drives chemoresistance. The team demonstrated that genetic...
Human monoclonals neutralize H5N1 clade 2.3.4.4b: Nature Communications report
A Nature Communications team isolated and characterized human monoclonal antibodies that neutralize clade 2.3.4.4b H5N1 hemagglutinin. The antibodies displayed broad-binding and potent...